{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-028590","form_type":"8-K","ticker":"URGN","cik":"0001668243","company_name":"UroGen Pharma Ltd.","filed_at":"2026-08-20T11:04:58+00:00","discovered_at":"2026-08-20T11:10:00.879658+00:00","generated_at":"2026-08-20T11:10:07.529610+00:00","sec_items":["8.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"UroGen secures exclusive option to license IntraGel's TumoCure for head and neck cancer; invests up to $7M","bullets":["On Aug 18, 2026, UroGen U.S. entered an Option and Research License Agreement with IntraGel Therapeutics for TumoCure (head and neck cancer).","UroGen obtained exclusive option for worldwide license to develop/commercialize TumoCure using IntraGel's SRGel biodegradable hydrogel platform.","Also obtained options for additional SRGel-based products with UroGen-designated compounds, plus non-exclusive research license.","UroGen agreed to invest up to $7,000,000 in IntraGel equity via Securities Purchase Agreement on same date."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-028590","json":"https://secwatch.observer/filing/0001437749-26-028590.json","markdown":"https://secwatch.observer/filing/0001437749-26-028590.md","text":"https://secwatch.observer/filing/0001437749-26-028590.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1668243/000143774926028590/0001437749-26-028590-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1668243/000143774926028590/urgn20260819_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-20T11:10:07.529610+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}